Appeals court sides with Gilead, Kite in CAR-T patent brawl, voiding Bristol Myers’ big $1.2B award
A new twist emerged Thursday in the long-running patent fight between Juno Therapeutics and Gilead’s Kite Pharma over CAR-T technology, one that gets Kite off the hook for more than $1.2 billion in damages.
The US Court of Appeals for the Federal Circuit reversed a previous decision awarding the money to Juno, ruling in a 19-page opinion that a patent owned by the Bristol Myers Squibb subsidiary and Sloan Kettering is invalid. All three panel judges agreed with Kite’s position, overturning a verdict from December 2019 after finding “substantial evidence does not support the jury’s verdict in Juno’s favor.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.